Regencell Bioscience shares rise 5.27% in premarket after securing exclusive rights to traditional Chinese medicine formulas via partnership agreements.

Regencell Bioscience Holdings Limited surged 5.27% in premarket trading, as the company announced a strategic partnership with traditional Chinese medicine practitioners to secure exclusive rights to their formulas. The firm focuses on R&D for neurocognitive disorder treatments using traditional Chinese medicine and has seen an 80.72% rise over the past five days and a 15,082.19% surge year-to-date.